Bioventus Inc. $BVS Shares Bought by EntryPoint Capital LLC

EntryPoint Capital LLC lifted its holdings in Bioventus Inc. (NYSE:BVS) by 7.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,371 shares of the company’s stock after acquiring an additional 2,048 shares during the period. EntryPoint Capital LLC’s holdings in Bioventus were worth $260,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its position in shares of Bioventus by 106.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after acquiring an additional 1,786 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Bioventus by 3,228.7% in the first quarter. GAMMA Investing LLC now owns 5,792 shares of the company’s stock worth $53,000 after acquiring an additional 5,618 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Bioventus by 23,761.5% in the first quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company’s stock worth $57,000 after acquiring an additional 6,178 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in shares of Bioventus in the fourth quarter worth $111,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Bioventus in the fourth quarter worth $113,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Trading Up 7.9%

NYSE BVS opened at $7.64 on Friday. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $14.38. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The company has a market capitalization of $631.67 million, a price-to-earnings ratio of -12.52 and a beta of 0.83. The company’s fifty day moving average price is $6.80 and its two-hundred day moving average price is $7.81.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BVS. Cantor Fitzgerald began coverage on shares of Bioventus in a research note on Monday, July 7th. They issued an “overweight” rating and a $12.00 target price for the company. Craig Hallum set a $15.00 target price on shares of Bioventus and gave the company a “buy” rating in a research note on Wednesday, May 7th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Bioventus currently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.